Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLK1 | P53350 | 1/20 | 0.52 |
| ▸ | SYK | P43405 | 1/20 | 0.51 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.47 |
| ▸ | IKBKB | O14920 | 11/20 | 0.46 |
| ▸ | CHUK | O15111 | 3/20 | 0.46 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.45 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13035473 | 0.81 | SYK (0.64) | PLK1SYKKDRIKBKBCHUK | |
| SCHEMBL6394544 | 0.78 | KDR (0.67) | PLK1SYKKDRIKBKBCHUK | |
| SCHEMBL6312915 | 0.78 | IGF1R (0.52) | SYKKDRMEN1NPC1RAB9A | |
| SCHEMBL4017779 | 0.76 | NPC1 (0.50) | SYKKDRLRRK2IRAK4MEN1 | |
| SCHEMBL17484071 | 0.75 | KDR (0.59) | PLK1SYKKDRIKBKBCHUK | |
| SCHEMBL3388994 | 0.74 | IGF1R (0.55) | MEN1NPC1RAB9AKMT2A | |
| SCHEMBL17801752 | 0.73 | SYK (0.69) | PLK1SYKKDRLRRK2IKBKB | |
| SCHEMBL19836328 | 0.72 | DYRK1A (0.51) | SYKIKBKBCHUKRIPK1 | |
| SCHEMBL6317977 | 0.72 | IGF1R (0.57) | RAB9A | |
| SCHEMBL6311516 | 0.72 | KDM1A (0.49) | MEN1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
| US-20100298314-A1 | NOVEL JNK INHIBITORS | SCHERING CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298314-A1 | NOVEL JNK INHIBITORS | MAPK1, MAPKAPK2, MAP4K2 | PLK1 685/4885SYK 1187/4885KDR 2419/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.